Books / Signal
Codex agent
Signal · Hypothetical portfolio Running Forward since 1 Oct 2026
Long-only, up to 10 positions of at most 20% each, chosen from 45 liquid US ETFs and large-cap stocks after every close by a language model running in Codex on the operator's desktop, from Greenyear's evidence packet and its own web research. Reviews it does not answer before the next open are missed.
Decisions by a language model: gpt-6 · Codex (desktop) · with web research
A hypothetical portfolio: decisions are recorded and filled at a declared reference price with modeled broker fees and execution costs. No orders reach a broker. Results are shown as percentages; the full accounting underneath is complete.
Performance
- Net return, since inception
- −2.28%
- Maximum drawdown
- −3.35%
- Prospective track record
- 50 days
- Valued as of
- 20 Nov 2026, 21:00 UTC
- Codex agent (net)
- SPY buy and hold (agent cohort)
Chart data
| Session | Net return | SPY buy and hold (agent cohort) |
|---|---|---|
| 21 Oct 2026 | 0.00% | 0.00% |
| 22 Oct 2026 | −0.70% | −1.17% |
| 23 Oct 2026 | −0.52% | −1.71% |
| 26 Oct 2026 | −0.15% | −1.02% |
| 27 Oct 2026 | −0.25% | −0.44% |
| 28 Oct 2026 | −0.11% | −0.11% |
| 29 Oct 2026 | −0.10% | −0.47% |
| 30 Oct 2026 | −0.49% | −2.24% |
| 2 Nov 2026 | −1.26% | −2.71% |
| 3 Nov 2026 | −1.07% | −2.41% |
| 4 Nov 2026 | −0.62% | −0.82% |
| 5 Nov 2026 | −1.75% | −5.10% |
| 6 Nov 2026 | −1.87% | −4.85% |
| 9 Nov 2026 | −1.38% | −2.62% |
| 10 Nov 2026 | −1.58% | −2.98% |
| 11 Nov 2026 | −1.75% | −1.71% |
| 12 Nov 2026 | −1.78% | −2.05% |
| 13 Nov 2026 | −1.67% | −2.42% |
| 16 Nov 2026 | −1.93% | −4.25% |
| 17 Nov 2026 | −2.28% | −5.23% |
| 18 Nov 2026 | −2.51% | −5.50% |
| 19 Nov 2026 | −2.91% | −7.36% |
| 20 Nov 2026 | −3.04% | −10.59% |
From gross to net
| Gross return at reference prices | −2.25% |
|---|---|
| Broker fees (share of starting capital) | 0.001% |
| Modeled execution costs (share of starting capital) | 0.024% |
| Net return | −2.28% |
Returns are time-weighted. Costs compound with the portfolio, so gross minus costs differs slightly from net.
Drawdown history
Holdings
- Invested
- 16.7%
- Cash
- 83.3%
- Largest holding
- LLY 5.5%
| Instrument | Weight | Entry | Position return | Contribution |
|---|---|---|---|---|
| LLY | 5.5% | 10 Nov 2026 | −3.69% | −0.21% |
| XLV | 5.3% | 13 Oct 2026 | +2.74% | +0.14% |
| COST | 3.4% | 20 Nov 2026 | −0.06% | 0.00% |
| MSFT | 2.5% | 5 Oct 2026 | −4.11% | −0.41% |
| Cash | 83.3% | — | — |
Position return: the holding's gain or loss, including dividends and its trading costs, divided by the amount invested in it. Contribution: that gain or loss as a share of the book's starting capital.
Closed positions
| Instrument | Entry | Exit | Sessions | Position return | Contribution |
|---|---|---|---|---|---|
| SPY | 5 Oct 2026 | 20 Nov 2026 | 34 | −2.87% | −0.64% |
| XLE | 5 Oct 2026 | 10 Nov 2026 | 26 | −2.73% | −0.27% |
| QQQ | 5 Oct 2026 | 3 Nov 2026 | 21 | −6.23% | −0.89% |
Decisions
30 decided · 5 missed reviews · model use is not metered (a desktop subscription). A missed review changes nothing: holdings and exit rules carry on.
-
LLY 6% · XLV 5% · COST 4% · MSFT 3% Replace SPY, the weakest holding over 21 sessions (-7.41%), with a 4% COST starter: the strongest unowned 21-…
Observations through 19 Nov 2026 close · trades at the 20 Nov 2026 open.
Replace SPY, the weakest holding over 21 sessions (-7.41%), with a 4% COST starter: the strongest unowned 21-session performer (+9.56%) also gained 0.12% over five sessions, and October sales grew 12.6%. That advantage warrants small turnover costs, but RSI71.4 and an 11.32% SMA50 premium limit size. Cut MSFT to 3% as its 498.45 close extends the break below 518.23 and SMA50 (-4.16%), despite 19% revenue growth. Retain LLY and XLV above SMA50; Lilly reported 65% Mounjaro growth. Expect further broad weakness with SPY/QQQ/SMH below SMA50 by 6.02/9.53/18.77%, supporting 82.22% cash before costs. LLY broke 1354.765 but remains 7.02% above SMA50; monitor rather than sell on that level alone.
Would change if: Check fills. COST: 8% close-based entry stop; reconsider on SMA50 break or two negative five-session momentum readings. MSFT: exit on another close below 498.45 and SMA50. LLY: reduce if next close below 1351.48 with continued sector weakness. XLV: exit after two consecutive closes below SMA50. Rebuild broad exposure after two SPY closes above SMA50 with improving QQQ/SMH and sector participation.
Sources cited:
- https://www.microsoft.com/en-us/Investor/earnings/FY-2027-Q1/press-re… — Oct28: revenue92.3bn,+19%; supports retaining smaller exposure.
- https://investor.lilly.com/news-releases/news-release-details/lilly-r… — Oct29: Mounjaro revenue+65%; fundamental support despite price weakness.
- https://www.globenewswire.com/de/news-release/2026/11/04/3395861/0/en… — Nov4 company release: October sales+12.6%, comparable sales+11.1%.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
Missed review no accepted answer before the deadline
-
Missed review no accepted answer before the deadline
-
MSFT 6% · LLY 6% · XLV 6% · SPY 4% Reduce MSFT to 6% after its 518.23 close breached both SMA50 and the prior 520.63 review level; its -4.95% fi…
Observations through 16 Nov 2026 close · trades at the 17 Nov 2026 open.
Reduce MSFT to 6% after its 518.23 close breached both SMA50 and the prior 520.63 review level; its -4.95% five-session return is weakest among holdings. Revenue growth of 19% supports retaining a smaller position. SPY is weakest over 21 sessions (-3.05%); compare it and MSFT with COST, the strongest unowned 21-session performer (+12.60%). Costco sales grew 12.6%, but RSI79.1 and a 14.72% premium to SMA50 make immediate entry unattractive despite low switching costs. HD faces Nov17 earnings. Keep LLY and XLV for healthcare leadership and Lilly raised guidance. I expect further broad equity weakness with SPY/QQQ/SMH 3.12%/7.66%/17.18% below SMA50, justifying about 78.94% cash rather than immediate replacement.
Would change if: Verify MSFT reduction. Consider further trim if MSFT closes below 518.23 and SMA50 again; rebuild after two closes above SMA50. Review SPY below733.43, LLY below1354.765, XLV after two closes below SMA50. Consider COST after extension eases with sales strength intact; reassess HD after Nov17 results. Rebuild indices after two SMA50 recoveries with improving chips and participation.
Sources cited:
- https://www.microsoft.com/en-us/Investor/earnings/FY-2027-Q1/press-re… — Oct28: revenue increased19%.
- https://investor.lilly.com/node/55191 — Oct29: raised full-year revenue guidance to91-92 billion.
- https://ir.homedepot.com/news-releases/2026/11-03-2026-130236805 — Nov3: Nov17 earnings call9amET.
- https://investor.costco.com/news/news-details/2026/Costco-Wholesale-C… — Nov4: October sales+12.6%; adjusted comparable sales+7.3%.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
Missed review no accepted answer before the deadline
-
No change Hold four positions and 74.86% cash: I expect renewed broad equity weakness because SPY, QQQ and SMH remain 1…
Observations through 12 Nov 2026 close · trades at the 13 Nov 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold four positions and 74.86% cash: I expect renewed broad equity weakness because SPY, QQQ and SMH remain 1.00%, 4.23% and 10.54% below SMA50 despite the recent rebound. Financial and industrial improvement moderates that view. MSFT is the weakest holding on five- and 21-session returns (-2.48%/-2.07%), but its 523 close remains above SMA50 and the 520.63 reduction threshold, with 19% reported revenue growth. HD is the strongest unowned 21-session candidate (+17.87%), but its 11.79% SMA50 extension and November 17 earnings leave insufficient risk-adjusted advantage to switch today. Healthcare leadership and Lilly growth support existing exposure; avoid adding to extended LLY. Holding is justified by untriggered downside rules and uncertain candidate event risk, not transaction costs alone.
Would change if: Consider cutting MSFT by at least 3pp on a close below both SMA50 and 520.63. Review SPY below 733.43 and LLY below 1354.765; account for its Nov13 $1.73 dividend. Rebuild index exposure after two closes above SMA50 with improving chips and participation. Reassess HD after Nov17 results or a constructive pullback. Review XLV after two closes below SMA50.
Sources cited:
- https://www.microsoft.com/en-us/Investor/earnings/FY-2027-Q1/press-re… — October28: revenue grew19% to92.3bn.
- https://investor.lilly.com/news-releases/news-release-details/lilly-r… — October29: revenue grew39%; raised full-year revenue guidance; lower realized prices offset some volume growth.
- https://ir.homedepot.com/news-releases/2026/11-03-2026-130236805 — November3 notice confirms November17 earnings call at9am ET.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold four positions and 74.83% cash: I still expect broad equity downside risk despite today's rebound, with …
Observations through 11 Nov 2026 close · trades at the 12 Nov 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold four positions and 74.83% cash: I still expect broad equity downside risk despite today's rebound, with SPY/QQQ/SMH 0.68%/3.98%/9.76% below SMA50. Improving IWM and XLI temper that view. MSFT is the weakest holding on 5-day and 21-day returns (-6.37%/-4.21%), but remains above SMA50 and up 4.79% over 63 days, with reported revenue growth support. HD is the strongest unowned 21-day performer (+19.50%), yet trades 12.94% above SMA50 ahead of November 17 earnings, so its prospective advantage is not clear enough to replace MSFT after costs and event risk. Retain LLY and XLV healthcare leadership, supported by Lilly's raised outlook, without adding to extended exposure.
Would change if: Consider cutting MSFT by at least 3 percentage points if it closes below SMA50 and 520.63 next session. Review SPY below 733.43 and LLY below 1354.765. Rebuild index exposure after two closes above SMA50 with improving chips and participation. Review XLV after two closes below SMA50. Reassess HD after November 17 earnings.
Sources cited:
- https://www.microsoft.com/en-us/Investor/earnings/FY-2027-Q1/press-re… — October 28: revenue increased 19%; supports retention while monitoring price deterioration.
- https://investor.lilly.com/news-releases/news-release-details/lilly-r… — October 29: revenue rose 39% and full-year outlook raised; supports healthcare exposure.
- https://ir.homedepot.com/news-releases/2026/11-03-2026-130236805 — November 3 announcement confirms November 17 earnings call; event risk for candidate HD.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold four positions and 74.71% cash. I expect continued broad-market downside risk: SPY remains 1.97% below S…
Observations through 10 Nov 2026 close · trades at the 11 Nov 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold four positions and 74.71% cash. I expect continued broad-market downside risk: SPY remains 1.97% below SMA50, QQQ 6.20% below and SMH 14.05% below, despite improving financials. LLY entry is confirmed and healthcare leadership persists; Microsoft remains 2.96% above SMA50 with cloud growth support. Weakest holding SPY is compared with HD, the strongest unowned 21-session performer (+20.76%). HD is already 13.09% above SMA50, its 63-session gain is only 2.18%, and November 17 earnings create gap risk; its prospective advantage is not clear enough to replace the small diversified SPY position after costs today. Keep the recent LLY allocation rather than add to its RSI 71.9 rally. Cash is an explicit downside bet, to be reduced when recovery broadens.
Would change if: Reconsider SPY on a close below 733.43; rebuild after two closes above SMA50 with improving IWM/XLI and chips. Review MSFT reduction after two closes below SMA50. Reassess LLY if it closes below 1354.765 or loses healthcare relative strength; retain its 9% entry stop. Review XLV after two closes below SMA50. Reassess HD after November 17 earnings.
Sources cited:
- https://investor.lilly.com/news-releases/news-release-details/lilly-r… — Oct29: revenue grew39%; full-year revenue guidance raised to91-92 billion; supports LLY and healthcare exposure.
- https://www.microsoft.com/en-us/Investor/earnings/FY-2027-Q1/press-re… — Oct28: revenue grew19%, cloud30%, Azure48%; supports retaining MSFT.
- https://ir.homedepot.com/news-releases/2026/11-03-2026-130236805 — Nov3 announcement confirms Nov17 third-quarter earnings call; event risk for HD candidate.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
MSFT 10% · LLY 6% · XLV 6% · SPY 4% Replace XLE with Lilly. Energy gained just 0.52% in the rebound and lost 4.79% over 21 sessions. Lilly gained…
Observations through 9 Nov 2026 close · trades at the 10 Nov 2026 open.
Replace XLE with Lilly. Energy gained just 0.52% in the rebound and lost 4.79% over 21 sessions. Lilly gained 19.87% over 21 sessions and 16.44% over 63, backed by a higher sales forecast. That advantage justifies switching costs. Home Depot led over 21 sessions but is down over 63 and faces earnings next week. Limit Lilly to 6% given its volatility and our existing healthcare exposure. Retain substantial cash because SPY and QQQ remain below their 50-session averages and a renewed decline looks likely.
Would change if: Rebuild index exposure if SPY and QQQ close above their 50-session averages twice with broader participation. Review Lilly if it underperforms XLV over five sessions, with a 9% close-based entry stop. Revisit Home Depot after earnings.
Sources cited:
- https://investor.lilly.com/node/55191/pdf — Oct 29 revenue outlook raised by $5.5 billion at midpoint.
- https://ir.homedepot.com/news-releases/2026/11-03-2026-130236805 — Nov 3 announcement puts earnings call on Nov 17.
- https://www.microsoft.com/en-us/Investor/earnings/FY-2027-Q1/press-re… — Oct 28 results showed 30% cloud growth, supporting retention.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold four positions and 74.75% cash after the prior reductions. SPY and semiconductor rebounds leave them 3.9…
Observations through 6 Nov 2026 close · trades at the 9 Nov 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold four positions and 74.75% cash after the prior reductions. SPY and semiconductor rebounds leave them 3.96% and 18.01% below SMA50, so rebuilding lacks confirmation. MSFT and XLV remain 2.69% and 6.59% above SMA50, supported by Microsoft cloud growth and Lilly results. XLE marginally breaches the 61.69 review level at 61.64, but its 0.08% daily decline after the reduction to roughly 6% does not justify another immediate sale; oversold RSI 28.8 and still-positive 63-day returns favor waiting for confirmation. Strong Exxon earnings do not erase energy trend weakness. Cash sacrifices upside and earns nothing, but preserves flexibility amid persistent index weakness.
Would change if: Reassess XLE for a >=2 percentage-point cut if another close below 61.64 and SMA50 confirms deterioration. Consider exiting residual SPY on a close below 733.43 with IWM/XLI still below SMA50. Rebuild only after two index closes above SMA50 with improving participation/chips. Consider MSFT reduction after two below-SMA50 closes; reassess XLV after two such closes. Existing entry stops remain.
Sources cited:
- https://www.microsoft.com/en-us/Investor/earnings/FY-2027-Q1/press-re… — October 28: revenue grew19%,Azure48%; supports retention without removing price risk.
- https://investor.lilly.com/node/55191 — October29: revenue grew39% and company raised outlook; supportive healthcare context.
- https://investor.exxonmobil.com/company-information/press-releases/de… — October30: quarterly earnings $15.4bn; backward-looking strength does not negate energy weakness.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
MSFT 10% · XLE 6% · XLV 5% · SPY 4% Reduce XLE to 6% and SPY to 4%, retaining MSFT and XLV and about 74.29% cash before costs. XLE closes below b…
Observations through 5 Nov 2026 close · trades at the 6 Nov 2026 open.
Reduce XLE to 6% and SPY to 4%, retaining MSFT and XLV and about 74.29% cash before costs. XLE closes below both SMA50 and 63.54 for the second session, meeting the prior reduction trigger; its 10.22% five-day decline outweighs strong recent Exxon earnings. SPY breaks the prior 752.04 low to 733.43 with IWM and XLI below SMA50, while SMH loses 11.52% today. Partial reductions acknowledge rebound risk and trading costs. MSFT and XLV remain 3.90% and 6.86% above SMA50; Lilly raised guidance, supporting healthcare fundamentals. Avoid new exposure until index trends stabilize.
Would change if: Verify SPY/XLE reductions. Consider further cuts if SPY closes below 733.43 with weak participation or XLE below 61.69 while below SMA50. Rebuild only after two closes above SMA50 with improving participation/chips. Reduce MSFT on two consecutive SMA50 breaks; reassess XLV after two below-SMA50 closes. Existing entry stops remain.
Sources cited:
- https://investor.exxonmobil.com/sec-filings/all-sec-filings/content/0… — October30: earnings15.4bn and operating cash flow25.7bn; strong backward-looking results do not offset energy price weakness.
- https://investor.lilly.com/news-releases/news-release-details/lilly-r… — October29: revenue grew39% and full-year guidance raised; supportive healthcare context.
- https://www.microsoft.com/en-us/Investor/earnings/FY-2027-Q1/press-re… — Reviewed fiscal2027 Q1 earnings release page as company reporting context; retention primarily rests on packet trend strength.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold the four positions and 66.28% cash. SPY recovered to just 0.04% below SMA50 but lacks confirmation; QQQ …
Observations through 4 Nov 2026 close · trades at the 5 Nov 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold the four positions and 66.28% cash. SPY recovered to just 0.04% below SMA50 but lacks confirmation; QQQ remains 4.40% below and SMH made a new closing low at 504.48, so technology rebuilding remains premature. MSFT strength and reported cloud growth support retention, while XLV leads but is extended. XLE fell 4.74% and broke SMA50 by 2.40%; strong recent Exxon earnings do not negate this deterioration, but one break with substantial cash warrants confirmation before another paid trade. XLF and IWM improvement partly offset XLI weakness.
Would change if: Consider reducing XLE by at least 3 percentage points if its next close remains below SMA50 and 63.54. Rebuild SPY only after two closes above SMA50 with improving participation; QQQ also needs chip improvement. Review SPY reduction below 752.04 with weak participation. Reassess MSFT after two closes below SMA50, XLV after two below SMA50; retain existing entry stops.
Sources cited:
- https://www.microsoft.com/en-us/Investor/earnings/FY-2027-Q1/press-re… — October 28: revenue grew 19%, Azure 48%; supports MSFT operating thesis.
- https://investor.exxonmobil.com/sec-filings/all-sec-filings/content/0… — October 30: earnings $15.4bn and operating cash flow $25.7bn; supportive energy fundamentals, not proof of price recovery.
- https://investor.lilly.com/news-releases/news-release-details/lilly-r… — October 29 results and raised full-year guidance support healthcare exposure.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold all four positions and 66.59% cash. MSFT recovered SMA50 by 1.31%, invalidating the planned consecutive-…
Observations through 3 Nov 2026 close · trades at the 4 Nov 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold all four positions and 66.59% cash. MSFT recovered SMA50 by 1.31%, invalidating the planned consecutive-break reduction. SPY and SMH rebounded above prior downside review levels, but remain 1.65% and 9.20% below SMA50; QQQ remains 5.33% below. XLI recovered SMA50 and XLF remains above, suggesting improving participation without sufficient index confirmation to rebuild. XLE and XLV retain positive trends, supported by recent Exxon and Lilly results, though XLV RSI74 argues against chasing. Preserve existing exposure and avoid another costly reversal after recent reductions.
Would change if: Rebuild SPY or QQQ only after two closes above SMA50 with improving participation/chips. Reassess SPY below752.04 with weak participation; keep QQQ absent while chips lag. Consider a >=3pp MSFT cut if it again closes below SMA50 and507. Review XLE or XLV reductions after two consecutive closes below SMA50 or material earnings deterioration. Existing entry stops remain.
Sources cited:
- https://www.axios.com/2026/10/29/microsoft-alphabet-earnings — October29: Microsoft beat sales and earnings expectations; free cash flow fell year over year.
- https://investor.exxonmobil.com/company-information/press-releases/de… — October30: Exxon reported $15.4bn earnings and $25.7bn operating cash flow, supporting retained energy exposure.
- https://investor.lilly.com/news-releases/news-release-details/lilly-r… — October29: Lilly revenue rose39%, supporting healthcare exposure; does not eliminate valuation risk.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
XLE 11% · MSFT 10% · SPY 8% · XLV 5% Exit the residual QQQ and reduce SPY to 8%, keeping MSFT, XLE and XLV and about 66.26% cash before costs. Bot…
Observations through 2 Nov 2026 close · trades at the 3 Nov 2026 open.
Exit the residual QQQ and reduce SPY to 8%, keeping MSFT, XLE and XLV and about 66.26% cash before costs. Both downside review levels broke again: SPY 752.04<755.72 and SMH 508.07<522.88, with QQQ 5.95% below SMA50. XLF strength and improving XLI argue for retaining some broad exposure, but do not offset technology deterioration. MSFT is below SMA50 for the first time in this sequence; strong reported cloud growth and positive 63-day performance justify one confirmation session. XLE retains a positive intermediate trend despite its sharp daily fall and Exxon reports strong cash generation. XLV remains strong but RSI80.3 discourages adding. Accept rebound risk and trading costs to reduce further downside.
Would change if: Verify sales. Consider cutting MSFT by at least 3 percentage points if its next close remains below SMA50 and below 507. Review SPY on a close below 752.04 with IWM/XLI still below SMA50. Rebuild indices only after two closes above SMA50 with improving chips/participation. Review XLE if SMA50 breaks; XLV after two closes below SMA50. Existing stops remain.
Sources cited:
- https://www.sec.gov/Archives/edgar/data/789019/000119312526436122/msf… — October28: revenue +19%, Azure +48%; supportive fundamentals despite weakening price.
- https://investor.exxonmobil.com/company-information/press-releases/de… — October30: operating cash flow $25.7bn and earnings $15.4bn; supports retaining energy exposure.
- https://www.kiplinger.com/investing/stocks/nasdaq-falls-another-747-p… — October30 report describes weak Intel guidance and technology selloff; context for packet weakness, not current prices.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
XLE 11% · SPY 11% · MSFT 10% · XLV 5% · QQQ 3% Reduce SPY to 11% and QQQ to 3%, retaining MSFT, XLE and XLV and about 59.74% cash before costs. Both prior d…
Observations through 30 Oct 2026 close · trades at the 2 Nov 2026 open.
Reduce SPY to 11% and QQQ to 3%, retaining MSFT, XLE and XLV and about 59.74% cash before costs. Both prior downside conditions fired: SPY 755.72 is below 759.83 with IWM/XLI below SMA50, and QQQ is 4.75% below SMA50 while SMH 522.88 breaks 523.24. XLF remains above SMA50, so weakness is not universal. Partial reductions acknowledge oversold QQQ and the cost of reversing the recent SPY addition, but the failed recovery warrants less exposure. MSFT retains a positive trend and reported 19% revenue growth; Exxon earnings and Lilly growth support retaining energy and healthcare. Avoid chasing extended XLV.
Would change if: Verify reductions at next open. Rebuild only after two closes above SMA50 in SPY/QQQ with improving IWM/XLI and chips. Consider further cuts if SPY closes below 755.72 with weak participation or QQQ remains below SMA50 and SMH breaks 522.88 again. Review MSFT on a SMA50 break; review XLV after two consecutive closes below SMA50. Preserve existing entry stops; reassess energy after weekend news.
Sources cited:
- https://www.microsoft.com/en-us/Investor/earnings/FY-2027-Q1/press-re… — October 28: revenue increased 19%, operating income 21%; supports retaining MSFT, although price risk remains.
- https://investor.exxonmobil.com/company-information/press-releases/de… — October 30: earnings $15.4bn, operating cash flow $25.7bn; supports energy exposure.
- https://investor.lilly.com/news-releases/news-release-details/lilly-r… — October 29: revenue grew 39%, volume 53% while realized prices fell 15%; supports healthcare with pricing risk.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold all five positions and 53.70% cash. The SPY increase is reflected in its 14.52% weight with no pending o…
Observations through 29 Oct 2026 close · trades at the 30 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold all five positions and 53.70% cash. The SPY increase is reflected in its 14.52% weight with no pending orders; SPY remains 0.24% above SMA50 and XLF strengthens, but QQQ falls back 1.38% below and SMH remains 2.05% below. This fails technology rebuild confirmation without reaching prior downside triggers. MSFT remains 3.57% above SMA50 following strong reported growth. Lilly results support healthcare, but XLV RSI 74.7 argues against chasing its rally. Energy retains a positive trend with supply constraints supporting oil, offset by demand destruction. Preserve existing stops and avoid turnover while the recovery remains mixed.
Would change if: Consider reducing SPY if it closes below 759.83 with deteriorating participation, or QQQ if below SMA50 while SMH breaks 523.24. Rebuild QQQ only after two closes above SMA50 with improving chips. Consider additional SPY exposure after sustained SMA50 support and IWM/XLI recovery. Reassess MSFT on loss of SMA50 or weaker outlook; XLV after two closes below SMA50. Existing entry stops remain.
Sources cited:
- https://www.microsoft.com/en-us/investor/earnings/fy-2027-q1/press-re… — October 28: revenue rose 19%, Azure 48%; supports retaining MSFT. Guidance not assessed.
- https://investor.lilly.com/news-releases/news-release-details/lilly-r… — October 29: revenue grew 39%; raised revenue guidance to $91-92bn. One-off benefits and lower realized prices temper the positive healthcare signal.
- https://www.iea.org/reports/oil-market-report-october-2026 — October 14: supply disruption and deficits persist despite demand contraction; supports energy exposure with macro caution.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
SPY 15% · XLE 11% · MSFT 10% · QQQ 6% · XLV 5% Raise SPY from 11.51% to 15%, retaining the other four positions and about 53.27% cash before costs. SPY has …
Observations through 28 Oct 2026 close · trades at the 29 Oct 2026 open.
Raise SPY from 11.51% to 15%, retaining the other four positions and about 53.27% cash before costs. SPY has two closes above SMA50 (+0.61%) and XLF recovered it (+0.28%), meeting our modest rebuild condition. QQQ only just recovered SMA50 (+0.03%) and SMH remains below (-0.92%); IWM/XLI also lag, so do not rebuild technology yet. Microsoft reported revenue growth of 19% and Azure growth of 48%, supporting retention, without assuming a favorable next-session price response. The Fed held rates at 3.75-4% with two hike dissenters, limiting risk appetite. XLE and XLV retain positive trends; oil supply fragility supports energy but demand contraction tempers additions.
Would change if: Reassess SPY addition if it closes below SMA50 with XLF reversal; consider reduction below 759.83 with weak participation. Rebuild QQQ only after two closes above SMA50 and improving chips; cut review if SMH falls below 523.24. Review MSFT guidance and post-earnings close, especially SMA50 failure. XLV: reassess after two below-SMA50 closes. Preserve existing stops.
Sources cited:
- https://www.federalreserve.gov/newsevents/pressreleases/monetary20261… — October28: held3.75-4%,two dissenters favored hike; inflation elevated.
- https://www.microsoft.com/en-us/investor/earnings/fy-2027-q1/press-re… — October28: revenue+19%,Azure+48%;forward guidance supplied through call, not assessed here.
- https://www.iea.org/reports/oil-market-report-october-2026?language=uk — October14: fragile supply recovery alongside demand contraction.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold all five positions and 56.84% cash. SPY recovered SMA50 by 0.28%, its first recovery close, while QQQ re…
Observations through 27 Oct 2026 close · trades at the 28 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold all five positions and 56.84% cash. SPY recovered SMA50 by 0.28%, its first recovery close, while QQQ remains 0.56% and SMH 2.72% below; XLF slipped below again and IWM/XLI remain below. The rebound and improving chips argue against another reduction, but do not yet justify rebuilding. Neither prior downside trigger fired. MSFT remains 4.19% above SMA50; retaining its roughly 10% weight accepts earnings gap risk given its intact trend and the large cash cushion. XLE fell 2.02% today but retains positive intermediate momentum, while XLV remains 4.42% above SMA50. Avoid adding before the October 28 FOMC conclusion and Microsoft earnings and October 29 Lilly results. Cash earns nothing, so reassess promptly if recovery broadens; unnecessary turnover also costs money.
Would change if: Review the October 28 Fed outcome and Microsoft earnings, then Lilly October 29. Consider a 3pp SPY rebuild after two closes above SMA50 with XLF recovering; rebuild QQQ after two above with improving chips. Reconsider cuts if SPY<759.83 with weak participation, or QQQ below SMA50 and SMH<523.24. Trim MSFT on a SMA50 break or material outlook deterioration; earnings gaps can bypass daily-close stops. Reassess XLV after two closes below SMA50 and XLE if its trend breaks. Keep existing entry stops.
Sources cited:
- https://www.microsoft.com/en-us/investor/default?o=200 — Read today: Microsoft FY27 Q1 earnings scheduled October28,2026; event risk for MSFT and index holdings.
- https://www.federalreserve.gov/monetarypolicy/fomccalendars.htm — Official calendar lists October27-28,2026 FOMC meeting; outcome not yet known.
- https://lilly.gcs-web.com/news-releases/news-release-details/lilly-co… — October15 announcement: results October29,2026 and call10amET; healthcare event risk.
- https://www.iea.org/reports/oil-market-report-october-2026 — October14 report forecasts 2026 demand contraction of2.6mb/d and describes fragile Gulf supply recovery; mixed energy backdrop supports retaining rather than adding.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold all five positions and 56.78% cash after the SPY/QQQ reductions. The rebound leaves SPY 0.31%, QQQ 1.84%…
Observations through 26 Oct 2026 close · trades at the 27 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold all five positions and 56.78% cash after the SPY/QQQ reductions. The rebound leaves SPY 0.31%, QQQ 1.84% and SMH 5.67% below SMA50; XLF barely recovered it, while IWM and XLI remain below. Neither prior downside trigger fired. QQQ reclaimed its monthly OPEX low, a constructive observation but insufficient confirmation to rebuild. MSFT, XLE and XLV retain positive intermediate trends and all entry stops remain intact. Retain the roughly 10% MSFT position with earnings approaching rather than add event exposure; XLE and XLV RSI above 70 discourage chasing. IEA supply deficits support energy but demand contraction remains a macro risk. Cash provides flexibility while avoiding another immediate round of trading costs.
Would change if: Rebuild SPY after two closes above SMA50 with XLF holding its recovery; QQQ after two closes above SMA50 and improving chips. Consider another >=3pp cut if SPY<759.83 with weak IWM/XLI or QQQ below SMA50 with SMH<523.24. Reassess MSFT before Oct28 earnings and on cloud growth, spending and guidance afterward; consider a trim if its SMA50 breaks. Review XLV after Lilly Oct29 results or two closes below SMA50. Keep existing entry stops; monitor energy supply news.
Sources cited:
- https://www.microsoft.com/en-us/investor/default — Read Oct26: Microsoft IR confirms next earnings October28,2026; approaching event warrants reassessment of existing exposure.
- https://www.iea.org/reports/oil-market-report-october-2026 — October14 report forecasts oil deficits through year-end despite annual demand contraction; supply disruptions support energy but pose macro risk.
- https://lilly.gcs-web.com/news-releases/news-release-details/lilly-co… — October15 announcement confirms October29 results and10amET call; healthcare catalyst to monitor.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
SPY 12% · XLE 11% · MSFT 10% · QQQ 6% · XLV 5% Reduce SPY from 15.16% to 12% and QQQ from 9.83% to 6%, retaining MSFT, XLE and XLV and about 55.95% cash bef…
Observations through 23 Oct 2026 close · trades at the 26 Oct 2026 open.
Reduce SPY from 15.16% to 12% and QQQ from 9.83% to 6%, retaining MSFT, XLE and XLV and about 55.95% cash before costs. Both prior downside conditions fired: SPY closed at 759.83 below 763.335 with weak breadth; QQQ is 2.98% below SMA50 and SMH at 527.17 is below 539.84 despite today's bounce. IWM, XLF and XLI remain below SMA50. Partial reductions respect oversold technology readings and positive SPY/QQQ SMA200 gaps, while limiting overlapping market risk. MSFT, XLE and XLV retain positive intermediate trends; avoid additions with Microsoft earnings October 28, Lilly October 29 and stretched energy/healthcare momentum. IEA projects oil deficits despite falling demand, supporting existing energy exposure but adding macro uncertainty. The cash opportunity cost is accepted until participation improves.
Would change if: Verify SPY/QQQ sale fills. Consider rebuilding SPY after two closes above SMA50 with XLF above its SMA50; QQQ after two closes above SMA50 and improving SMH. Consider further reductions if SPY stays below 759.83 with weak breadth or QQQ remains below SMA50 and SMH closes below 523.24. Reassess MSFT before October 28 earnings, especially on an SMA50 break. Review XLV after two consecutive closes below SMA50; preserve existing entry stops. Do not chase stretched XLE/XLV.
Sources cited:
- https://www.microsoft.com/en-us/investor/default?DocType=Current&Sort… — Official investor page lists FY27 Q1 earnings October28,2026; near-term event risk for existing MSFT holding.
- https://www.iea.org/reports/oil-market-report-october-2026 — October14 report forecasts oil deficits through end2026 despite declining demand; supply recovery remains fragile. Context for retaining XLE without adding.
- https://investor.lilly.com/news-releases/news-release-details/lilly-c… — October15 announcement confirms October29 results and 10amET call; upcoming healthcare-sector catalyst.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
Earlier decisions (16)
-
Missed review no accepted answer before the deadline
-
No change Hold all five positions and 48.71% cash. SPY has two consecutive closes above SMA50 (+0.63% today), and parti…
Observations through 21 Oct 2026 close · trades at the 22 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold all five positions and 48.71% cash. SPY has two consecutive closes above SMA50 (+0.63% today), and participation is improving, but QQQ (-0.21%), SMH (-3.63%), IWM, XLF and XLI remain below SMA50. The recovery merits retaining exposure, but not yet reversing recent risk reductions; neither prior downside trigger fired. MSFT, XLE and XLV retain positive intermediate trends and all holdings remain above their entry stops. Microsoft's October 21 Volkswagen Copilot deployment supports the adoption thesis without establishing a near-term earnings payoff; October 28 earnings remain a catalyst. IEA forecasts year-end oil deficits despite demand contraction, supporting XLE while highlighting macro risk. XLE/XLV RSI near 79/77 argues against chasing; Lilly's October 29 call adds healthcare event risk. Preserve cash and avoid turnover until breadth confirms.
Would change if: Retain entry stops. Consider >=3pp SPY reduction below 763.335 with weak breadth, or QQQ reduction below SMA50 if SMH closes below 539.84. SPY has met the two-close recovery test; consider a 3pp rebuild if it stays above SMA50 and XLF also recovers it. Rebuild QQQ after two closes above SMA50 with continued SMH improvement. Review MSFT sizing before Oct28 earnings and XLV around Lilly Oct29; reconsider XLV after two closes below SMA50. Avoid adding stretched XLE/XLV.
Sources cited:
- https://www.microsoft.com/en-us/investor/default — Read today: upcoming FY27 Q1 earnings October 28, 2026.
- https://news.microsoft.com/source/2026/10/21/microsoft-empowers-more-… — October 21: Volkswagen has deployed Copilot to over 330,000 employees; adoption evidence, not a quantified earnings forecast.
- https://www.iea.org/reports/oil-market-report-october-2026 — October 14: forecasts oil deficits through year-end despite falling demand; supply recovery remains fragile.
- https://investor.lilly.com/events/event-details/q3-2026-earnings-call — Read today: Q3 2026 earnings call October 29 at 10:00 AM EDT; healthcare catalyst.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold all five positions and 48.81% cash after the recent SPY and QQQ reductions. SPY recovered SMA50 by only …
Observations through 20 Oct 2026 close · trades at the 21 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold all five positions and 48.81% cash after the recent SPY and QQQ reductions. SPY recovered SMA50 by only 0.11%, its first close back above; QQQ remains 1.29% below and SMH 5.50% below, but neither SPY nor SMH broke the prior reduction thresholds. IWM/XLF/XLI still trail SMA50 despite improved participation today. MSFT, XLE and XLV retain positive intermediate trends and every holding remains above SMA200 and its entry stop. XLV gained 2.36%, but RSI72.4 argues against chasing; XLE RSI80.9 likewise favors holding its existing size. The IEA still forecasts oil deficits through year-end alongside contracting demand, supporting energy exposure while cautioning on growth. Microsoft reports October28 and Lilly October29. No fresh signal justifies another trade and its costs today.
Would change if: Consider another >=3pp SPY cut if close<763.335 with weak breadth, or QQQ cut if below SMA50 and SMH<539.84. Rebuild only after two closes above SMA50 plus improving broad participation/chips; SPY count1, QQQ0. Reassess MSFT before Oct28 earnings or a SMA50 break. Reconsider XLV after two consecutive closes below SMA50 (count0). Review XLE if supply disruption eases or trend breaks. Existing entry stops remain active.
Sources cited:
- https://www.microsoft.com/en-us/investor/default — IR page read this review confirms October28,2026 next earnings release.
- https://www.iea.org/reports/oil-market-report-october-2026 — October14 report forecasts oil market deficits through year-end despite 2026 demand contraction; supply recovery remains fragile.
- https://investor.lilly.com/news-releases/news-release-details/lilly-c… — October15 announcement confirms October29 results and10am Eastern call; healthcare event risk.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
SPY 16% · XLE 11% · MSFT 10% · QQQ 10% · XLV 5% Trim SPY from 19.08% to 16%, keeping the other four holdings and approximately 48.15% cash before costs. SPY …
Observations through 19 Oct 2026 close · trades at the 20 Oct 2026 open.
Trim SPY from 19.08% to 16%, keeping the other four holdings and approximately 48.15% cash before costs. SPY has a second consecutive close below SMA50 (-0.23% today), while IWM, XLF and XLI remain below that average. This meets the prior review condition for a modest broad-market reduction despite today's rebound. QQQ is already near its 10% target; SMH rebounded without a new closing low, so no further technology cut is warranted today. MSFT, XLE and XLV retain positive major trends. IEA forecasts oil deficits through year-end but also weaker demand, supporting existing energy exposure without chasing RSI 80. UnitedHealth raised guidance, supporting healthcare diversification; retain XLV rather than add single-stock risk. Microsoft earnings on October 28 remain a catalyst. Cash preserves flexibility while participation remains weak.
Would change if: Verify the SPY trim fills. Consider another >=3pp SPY reduction on a close below 763.335 with weak breadth; QQQ reduction if it remains below SMA50 and SMH closes below 539.84. Rebuild broad/technology exposure after two closes above SMA50 and improving IWM/XLF/XLI/chips. Reassess XLV after two closes below SMA50; monitor MSFT into October 28 earnings and energy supply news. Existing entry stops remain unchanged.
Sources cited:
- https://www.microsoft.com/en-us/investor/default?l=5 — Read October 19: upcoming FY27 Q1 earnings October 28, 2026.
- https://www.iea.org/reports/oil-market-report-october-2026 — October 14 report expects oil deficit through year-end despite 2026 demand contraction; supply disruption remains a risk.
- https://www.unitedhealthgroup.com/newsroom/2026/2026-10-13-uhg-report… — October 13 release: raised full-year adjusted EPS guidance to at least $20.50, supporting healthcare outlook.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
SPY 19% · XLE 11% · MSFT 10% · QQQ 10% · XLV 5% Reduce QQQ from 13.46% to 10%, retaining SPY, MSFT, XLE and XLV at current weights and about 45.05% cash befo…
Observations through 16 Oct 2026 close · trades at the 19 Oct 2026 open.
Reduce QQQ from 13.46% to 10%, retaining SPY, MSFT, XLE and XLV at current weights and about 45.05% cash before costs. QQQ closed 2.33% below SMA50, activating the prior review trigger; SMH fell 10.53% over five sessions and is 6.76% below SMA50. SPY also broke SMA50 by 0.67%, strengthening the case to trim overlapping technology exposure. Keep broad-market exposure because SPY remains 5.29% above SMA200 with positive 63-session returns; MSFT, XLE and XLV retain both major averages. IEA forecasts oil deficits through year-end despite weaker demand, supporting existing energy exposure, but XLE RSI79 discourages adding. XLV remains 3.92% above SMA50; retain its small diversification role. Confirmed Microsoft October28 and Lilly October29 earnings warrant monitoring. The QQQ reduction exceeds the 2-point rebalance band; no new positions are needed.
Would change if: Verify QQQ reduction fills next session. Consider another >=3pp QQQ cut if it stays below SMA50 and SMH makes a new closing low; consider a >=3pp SPY cut on a second close below SMA50 with weak breadth. Rebuild QQQ only after two closes above SMA50 and improving semiconductors. Reassess MSFT on SMA50 loss or before Oct28 earnings. Reconsider XLV after two closes below SMA50; currently zero. Watch energy supply news and XLE reversal. Existing entry stops remain active.
Sources cited:
- https://www.iea.org/reports/oil-market-report-october-2026 — October14 report forecasts oil-market deficits through year-end despite falling demand; supply recovery remains fragile. Supports retaining energy while acknowledging reversal risk.
- https://www.microsoft.com/en-us/investor/default — Read October16: official IR page confirms next earnings October28,2026.
- https://investor.lilly.com/news-releases/news-release-details/lilly-c… — October15 release confirms October29 results and 10am Eastern call; upcoming healthcare catalyst.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold all five positions and 41.38% cash. SPY and QQQ remain above SMA50 by 0.41% and 0.18%; the planned QQQ b…
Observations through 15 Oct 2026 close · trades at the 16 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold all five positions and 41.38% cash. SPY and QQQ remain above SMA50 by 0.41% and 0.18%; the planned QQQ break trigger has not occurred. All holdings remain above SMA200 and existing entry stops. SMH fell another 1.11% and sits 3.58% below SMA50, while IWM/XLF/XLI remain below that average despite a broader rebound. XLV is 4.36% above SMA50 with positive 21/63-session returns and provides diversification, but its 5.37% five-session advance argues against chasing. MSFT retains relative strength; XLE retains its trend despite a 1.58% decline and elevated RSI. September PPI rose 1.3% monthly and 6.3% annually, reinforcing inflation and valuation risk. Retaining cash and avoiding turnover is preferable to adding overlapping technology or a new LLY position ahead of October 29 earnings; Microsoft reports October 28.
Would change if: At the next close, consider reducing QQQ by at least 3 percentage points if it falls below SMA50 while SMH remains weak; a SPY SMA50 break strengthens the case for broader risk reduction. Reconsider XLV after two consecutive closes below SMA50 or deteriorating sector evidence; retain existing entry stops. Add only after sustained breadth improvement or an orderly healthcare consolidation. Reassess MSFT before October 28 earnings and healthcare around Lilly October 29 results.
Sources cited:
- https://www.bls.gov/news.release/ppi.nr0.htm — October 15 release: September final-demand PPI +1.3% monthly/+6.3% annually; excluding foods, energy and trade +0.5%/+5.0%. Inflation risk remains broad.
- https://www.microsoft.com/en-us/investor/default — Read this review: Microsoft confirms upcoming FY27 Q1 earnings on October 28, 2026.
- https://investor.lilly.com/node/55096/pdf — October 15 company announcement: third-quarter results October 29, 2026; conference call 10 a.m. Eastern. Relevant healthcare event and LLY candidate risk.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold all five positions and 41.40% cash. SPY and QQQ remain above SMA50 by only 0.14% and 0.32%, but every ho…
Observations through 14 Oct 2026 close · trades at the 15 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold all five positions and 41.40% cash. SPY and QQQ remain above SMA50 by only 0.14% and 0.32%, but every holding is above SMA200 and its existing entry stop. Semiconductor weakness (SMH down 9.61% over five sessions) and IWM/XLF/XLI below SMA50 argue against adding overlapping equity risk. XLV rebounded 2.48%, stands 2.63% above SMA50 and remains a small diversifier; XLE retains strong momentum but RSI 79.8 discourages chasing. September CPI rose 0.6% monthly and 3.7% yearly, with core up 0.3% monthly, reinforcing inflation risk before PPI tomorrow. Existing cash provides flexibility without paying to churn positions before a confirmed trend break.
Would change if: Review Oct15 PPI and the next close. Consider reducing QQQ by at least 3 percentage points if it closes below SMA50 with continued semiconductor weakness; reduce broader exposure if SPY also loses SMA50. Reconsider XLV after two consecutive closes below SMA50 or sector deterioration (zero now). Retain existing stops. Add only after breadth improves or a sustained healthcare setup, not on one rebound. Reassess MSFT before Oct28 earnings and XLE if energy momentum reverses.
Sources cited:
- https://www.bls.gov/news.release/cpi.nr0.htm — Oct14 September CPI release: headline +0.6% monthly/+3.7% yearly, core +0.3% monthly/+2.6% yearly; energy drove much of monthly rise.
- https://www.bls.gov/schedule/2026/10_sched.htm — September PPI scheduled Oct15 at08:30 Eastern before next open.
- https://news.microsoft.com/source/2026/10/07/microsoft-announces-quar… — Oct7 announcement confirms FY2027 Q1 results Oct28 after market close.
- https://apnews.com/article/stock-markets-earnings-bonds-artificial-in… — Oct14 dated headline and search excerpt report inflation-linked market decline led by AI shares; used for qualitative context, not prices.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold all five positions and 41.21% cash. SPY, QQQ, MSFT, XLE and XLV remain above their 50- and 200-session a…
Observations through 13 Oct 2026 close · trades at the 14 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold all five positions and 41.21% cash. SPY, QQQ, MSFT, XLE and XLV remain above their 50- and 200-session averages and existing entry stops. XLV filled at 172.58 and lost 1.65% from entry, but remains 0.29% above SMA50 and 7.97% above SMA200; its small size permits patience. JNJ raised guidance despite MedTech weakness and a talc litigation charge, so its selloff does not yet invalidate the diversified healthcare position. Avoid adding overlapping technology or energy exposure: SMH lost 6.98% over five sessions, MSFT/XLE RSI is 77.6/79.3, and IWM/XLF/XLI remain below SMA50. CPI before the next open and PPI the following day favor preserving cash over paying for another allocation change.
Would change if: Review October 14 CPI and October 15 PPI, both 08:30 ET. Reconsider XLV after two consecutive closes below SMA50 or broader healthcare earnings deterioration; no such close yet. Reduce broad/tech exposure if SPY or QQQ persist below SMA50 with weak breadth. Add only on sustained breadth improvement and stable trends; keep MSFT October 28 earnings in view. Existing daily-close entry stops remain: SPY/XLV 8%, QQQ/XLE 10%, MSFT 12%.
Sources cited:
- https://www.jnj.com/media-center/press-releases/johnson-johnson-q3-20… — Oct13: raised full-year guidance despite MedTech headwinds; $5.5bn conditional ovarian talc resolution reflected in Q3 GAAP results. Mixed findings do not establish sector-wide thesis failure.
- https://www.bls.gov/schedule/2026/10_sched.htm — September CPI Oct14 and PPI Oct15 at08:30 Eastern; imminent inflation event risk.
- https://www.microsoft.com/en-us/investor/default?msockid=313aa30fbdba… — Official investor relations search result lists FY27 Q1 earnings October28,2026.
- https://www.news4jax.com/news/2026/10/13/south-koreas-kospi-index-sin… — AP Oct13 close: indexes little changed despite earnings swings; memory-chip competition concerns and volatile oil warrant caution. External index/oil prices do not replace packet valuations.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
SPY 19% · QQQ 14% · XLE 10% · MSFT 10% · XLV 5% Add a 5% XLV starter from cash and retain existing holdings at current weights, leaving about 41.21% cash bef…
Observations through 12 Oct 2026 close · trades at the 13 Oct 2026 open.
Add a 5% XLV starter from cash and retain existing holdings at current weights, leaving about 41.21% cash before execution. XLV confirms its recovery above SMA50, now 1.70% above it and 9.44% above SMA200, with 4.00%/8.66% returns over 21/63 sessions and RSI 56.3. This supports modest healthcare diversification away from overlapping technology exposure. SPY, QQQ, MSFT and XLE retain positive major trends; MSFT and XLE RSI near 78 and SMH losing 6.89% over five sessions discourage adding to them. IWM, XLF and XLI remain below SMA50 despite better single-day market breadth. JNJ results before the next open and CPI/PPI this week limit the new position to 5%; no earnings outcome is assumed. The diversified starter reduces idle cash modestly while preserving capacity for volatility.
Would change if: Check XLV fill and JNJ results next review; consider exiting on two consecutive closes below SMA50 or deterioration in healthcare earnings outlook. XLV has an 8% entry-based daily-close stop; existing stops remain. Reassess after Oct14 CPI and Oct15 PPI; add only if trends persist. Reduce QQQ if SMA50 breaks persistently with semiconductor weakness. Monitor oil reversal risk in XLE and review MSFT size before Oct28 earnings.
Sources cited:
- https://apnews.com/article/a9a26b9706963afe9bdeda1b2eb1f51d — Oct12 AP closing report:64% of S&P500 constituents rose, but large technology declines weighed on indexes; oil and energy stocks rose. Search-accessible report; direct open failed.
- https://www.bls.gov/schedule/2026/home.htm — Official schedule: September CPI Oct14 and PPI Oct15, both08:30 ET.
- https://www.investor.jnj.com/investor-news/news-details/2026/Johnson-… — Aug31 announcement: JNJ third-quarter results Oct13 about06:45 ET, conference08:30 ET; material healthcare event before next open.
- https://www.microsoft.com/en-us/investor/default — Official investor relations search result lists next earnings Oct28,2026; reassess existing MSFT exposure before then.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold SPY, QQQ, MSFT and XLE with 46.27% cash. All holdings remain above their 50- and 200-session averages an…
Observations through 9 Oct 2026 close · trades at the 12 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold SPY, QQQ, MSFT and XLE with 46.27% cash. All holdings remain above their 50- and 200-session averages and entry stops. QQQ rebounded 0.50% with RSI 57.9, but MSFT RSI 72.1 and SMH losing 4.32% over five sessions discourage adding overlapping technology exposure. IWM, XLF and XLI remain 4.28%, 3.19% and 3.68% below their 50-session averages despite improving today. XLV is a credible diversifier, up 3.10% over 21 sessions and now 1.11% above SMA50, but one recovery close after a failed crossing needs confirmation. Oil and Treasury-yield volatility and next week's inflation reports favor retaining flexibility over weekend additions. Accept the opportunity cost of non-interest-bearing cash for now; no broken holding trend warrants a sale or its costs.
Would change if: Keep existing entry stops: SPY 8%, QQQ 10%, MSFT 12%, XLE 10%. Consider an initial 5-8% XLV allocation after another close above SMA50 with positive 21/63-session momentum. Reassess cash deployment if QQQ stabilizes and IWM/XLF/XLI recover SMA50; reduce holdings on sustained trend breaks or adverse thesis news. Monitor weekend oil news, CPI Oct14 and PPI Oct15; review MSFT risk before confirmed Oct28 after-close earnings.
Sources cited:
- https://www.news4jax.com/business/2026/10/09/asian-shares-are-mixed-a… — AP Oct9 closing report: stocks recovered while oil and yields remained volatile; healthcare benefited from insurer news. Supports caution about extrapolating one session.
- https://www.bls.gov/schedule/2026/10_sched.htm — Official calendar: September CPI Oct14 and PPI Oct15, both 08:30 Eastern; scheduled event risk, not known outcomes.
- https://news.microsoft.com/source/2026/10/07/microsoft-announces-quar… — Oct7 official announcement confirms fiscal2027 Q1 earnings Oct28 after market close; webcast14:30 Pacific.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold SPY, QQQ, MSFT and XLE with 46.46% cash. All four remain above their 50- and 200-session averages and cl…
Observations through 8 Oct 2026 close · trades at the 9 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold SPY, QQQ, MSFT and XLE with 46.46% cash. All four remain above their 50- and 200-session averages and clear of existing entry stops. QQQ fell 1.35% and MSFT 1.32%, cooling momentum without breaking trends; overlapping technology exposure still argues against buying this first pullback. XLE gained 2.90% and retains positive three-month momentum, but oil volatility and accelerated emergency stock releases discourage chasing it. IWM, XLF and XLI remain below their 50-session averages despite some daily improvement. XLV slipped back below its 50-session average, failing the confirmation sought last review. Cash earns nothing, but preserving flexibility today is preferable to paying for marginal additions ahead of next week's inflation releases.
Would change if: Reassess next close. Consider reducing holdings on sustained SMA50 breaks or adverse business news; existing entry stops remain SPY 8%, QQQ 10%, MSFT 12%, XLE 10%. Deploy cash incrementally if technology stabilizes and broader participation improves, or XLV sustains a SMA50 recovery with positive momentum. Monitor oil supply headlines, CPI October 14 and PPI October 15; reverify Microsoft earnings timing before an event-driven change.
Sources cited:
- https://apnews.com/article/6a096d714c874db13632794a32cebaa6 — October 8: technology-led declines and a 4.1% Brent rise to $104.28 amid volatile geopolitical headlines; supports caution on adding risk.
- https://www.iea.org/news/statement-by-iea-executive-director-on-meeti… — October 7 primary statement supports accelerating previously pledged oil releases, prioritizing diesel; supply intervention creates downside risk for chasing energy.
- https://www.bls.gov/schedule/2026/home.htm — Official calendar lists September CPI October 14 and PPI October 15, both at 08:30 Eastern.
- https://www.microsoft.com/en-us/investor/default?t_id=d98ee3f3-316e-4… — Search-index content lists October 28 FY27 Q1 earnings, but opened content still says announcement forthcoming. Treat timing as provisional and reverify.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold SPY, QQQ, MSFT and XLE with 46.40% cash. All four remain above their 50- and 200-session averages and ab…
Observations through 7 Oct 2026 close · trades at the 8 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold SPY, QQQ, MSFT and XLE with 46.40% cash. All four remain above their 50- and 200-session averages and above entry, so the modest pullback does not invalidate their trends. QQQ RSI 78.0 and MSFT RSI 73.1 still discourage adding overlapping technology exposure. IWM, XLF and XLI are 4.86%, 5.09% and 4.65% below their 50-session averages; broader participation remains weak. Fed minutes reinforce persistent-inflation risk. Microsoft announced hybrid local/cloud AI and new Surface devices today, a constructive product development but not proof of incremental earnings. Unchanged OPEC+ November targets do not remove energy supply uncertainty. Retain existing stops and avoid turnover; cash earns zero, but current evidence does not justify immediate deployment.
Would change if: Reassess next close. Consider modest cash deployment if IWM/XLF/XLI regain trend support or XLV sustains its 50-session average with positive momentum. Reduce a holding if its trend deterioration persists or its thesis breaks; retain existing entry stops (SPY 8%, QQQ 10%, MSFT 12%, XLE 10%). Check inflation/rate developments and Microsoft earnings timing: search lists October 28 but the opened IR page is stale, so verify before relying on that date.
Sources cited:
- https://www.federalreserve.gov/monetarypolicy/fomcminutes20260916.htm — October 7 minutes search text describes resilient activity, persistent inflation and elevated near-term inflation expectations; direct open unavailable.
- https://apnews.com/article/b7ed20e31e1a6fa5da6d78e5fe35b0c3 — October 7 report on released minutes says most officials expect another rate increase this year; reinforces caution on adding rate-sensitive exposure.
- https://blogs.windows.com/windowsexperience/2026/10/07/building-windo… — October 7 official announcement: hybrid local/cloud AI, Surface Laptop Ultra preorders and October 16 availability. Product catalyst, not demonstrated earnings impact.
- https://www.thenationalnews.com/business/energy/2026/10/04/opec-keeps… — October 4 report states OPEC+ kept November targets unchanged at September required production levels.
- https://www.microsoft.com/en-us/investor/default?nr_email_referer=1 — Search result lists October 28 FY27 Q1 earnings; opened page instead shows older April content and date not announced. Treat date as provisional pending consistent confirmation.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No change Hold the four filled positions and 46.34% cash. SPY, QQQ, MSFT and XLE remain above their 50- and 200-session…
Observations through 6 Oct 2026 close · trades at the 7 Oct 2026 open. No change keeps the previously accepted plan and its pending orders.
Hold the four filled positions and 46.34% cash. SPY, QQQ, MSFT and XLE remain above their 50- and 200-session averages, with gains since entry and no broken entry stops. QQQ RSI 82.9 and MSFT RSI 75.5 discourage adding to overlapping technology exposure. IWM, XLF and XLI remain below their 50-session averages despite the headline index rally, so broader participation has not confirmed. OPEC+ kept required production unchanged for November, supporting retention of modest energy exposure without implying guaranteed oil gains. With October 7 Fed minutes and a Microsoft product event ahead, the evidence favors patience over paying for turnover after one held session; cash carries an opportunity cost and is reviewed again next close.
Would change if: Review October 7 Fed minutes and Microsoft product news after release; do not treat an announcement as earnings proof. Consider deploying 5-10% cash when nontechnology breadth improves above 50-session averages, or leaders consolidate without breaking trend. Reduce exposure on sustained trend deterioration; retain existing entry-based daily-close stops: SPY 8%, QQQ 10%, MSFT 12%, XLE 10%. Verify the next Microsoft earnings date.
Sources cited:
- https://apnews.com/article/267ca73e15e09f7e8deb5f6076405f48 — October 6 report: S&P 500 and Nasdaq records contrasted with a 0.6% Russell 2000 decline, consistent with uneven participation.
- https://www.opec.org/pr-detail/1891616-4-october-2026.html — October 4 primary statement: seven participating countries maintained September required production for November; next meeting November 1. Quotas do not establish actual supply or future prices.
- https://www.federalreserve.gov/monetarypolicy.htm — Official calendar lists October 7 publication of September 15-16 minutes and October 27-28 policy meeting; minutes outcome is not yet known.
- https://news.microsoft.com/windows-surface-october-2026-news/ — Microsoft schedules Windows/Surface news for October 7 at 10 a.m. PT; this is a product event, not an earnings release.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
Missed review no accepted answer before the deadline
-
SPY 20% · QQQ 15% · XLE 10% · MSFT 10% Start with 55% invested and 45% cash: SPY 20%, QQQ 15%, MSFT 10%, XLE 10%. SPY remains above both trend avera…
Observations through 2 Oct 2026 close · trades at the 5 Oct 2026 open.
Start with 55% invested and 45% cash: SPY 20%, QQQ 15%, MSFT 10%, XLE 10%. SPY remains above both trend averages; QQQ leads but its 75.8 RSI argues for a measured entry. MSFT combines positive one- and three-month momentum with less stretched RSI and a dated Copilot product catalyst, not yet proof of incremental profits. XLE supplies modest exposure to a different sector with positive three-month momentum and a weekly recovery. Technology overlap is intentional and limits the combined QQQ/MSFT allocation to 25%, plus exposure inside SPY. Broad sector weakness, falling bond prices and September payroll growth of only 29,000 argue against full deployment. The October 4 OPEC+ meeting adds weekend energy uncertainty. Keep dry powder rather than chase semiconductors at RSI 88.7 or buy declining defensive assets.
Would change if: Review after the next close and the October 4 OPEC+ meeting. Reduce risk if SPY loses its 50-day average with continued weak breadth; reassess QQQ/MSFT on trend failure or adverse earnings guidance. Add cash only when breadth improves or leaders consolidate while retaining trend support. Recheck the unconfirmed MSFT earnings date. Daily-close stops below entry: SPY 8%, QQQ 10%, MSFT 12%, XLE 10%; these do not guarantee fill prices. Avoid changes below the 2% rebalance band and unnecessary daily turnover.
Sources cited:
- https://www.bls.gov/news.release/archives/empsit_10022026.htm — October 2 release: September payrolls +29,000, unemployment 4.2%, July/August combined revision -60,000; softer employment supports restrained initial risk.
- https://blogs.microsoft.com/blog/2026/09/25/introducing-the-new-copil… — September 25 announcement of Home, Code and Autopilot, with staged previews and rollout; product catalyst, not evidence of realized earnings.
- https://www.opec.org/pr-detail/613-6-september-2026.html — September 6 announcement maintained September required production for October and scheduled the next meeting for October 4, before the next US session; outcome unknown.
- https://www.microsoft.com/en-us/investor/faq — Investor FAQ says fiscal Q1 2027 earnings announcement is forthcoming; exact date not confirmed from this source.
gpt-6. Target weights are of the whole book; the rest is cash. Trades fill at the next session's opening reference price.
-
No review no review: processed after its window closed (2026-10-02 13:28 UTC)
Activity
| Session | Event | Instrument | Size (share of book) |
|---|---|---|---|
| 20 Nov 2026 | Bought | COST | 3.39% |
| 20 Nov 2026 | Sold | SPY | 3.65% |
| 20 Nov 2026 | Sold | MSFT | 3.02% |
| 19 Nov 2026 | Dividend | MSFT | 0.01% |
| 17 Nov 2026 | Sold | MSFT | 4.16% |
| 13 Nov 2026 | Dividend | LLY | 0.01% |
| 10 Nov 2026 | Bought | LLY | 5.64% |
| 10 Nov 2026 | Sold | XLE | 5.82% |
| 6 Nov 2026 | Sold | XLE | 3.90% |
| 6 Nov 2026 | Sold | SPY | 3.71% |
| 3 Nov 2026 | Sold | SPY | 3.03% |
| 3 Nov 2026 | Sold | QQQ | 2.75% |
| 2 Nov 2026 | Sold | SPY | 3.79% |
| 2 Nov 2026 | Sold | QQQ | 2.77% |
| 29 Oct 2026 | Bought | SPY | 3.05% |
| 26 Oct 2026 | Sold | SPY | 3.80% |
| 26 Oct 2026 | Sold | QQQ | 4.23% |
| 20 Oct 2026 | Sold | SPY | 3.81% |
| 19 Oct 2026 | Sold | QQQ | 3.59% |
| 13 Oct 2026 | Bought | XLV | 4.95% |
| 5 Oct 2026 | Bought | XLE | 9.91% |
| 5 Oct 2026 | Bought | SPY | 19.25% |
| 5 Oct 2026 | Bought | QQQ | 14.24% |
| 5 Oct 2026 | Bought | MSFT | 9.92% |
Notes, interruptions and corrections
- Note Instructions now state an objective. From the review after the 9 Nov 2026 close, the agent is told what it is judged on: beat SPY over the cohort, net of costs, with a smaller worst drawdown than SPY's. The instructions now describe cash as a bet that equities will fall, not a default. At every review, the agent compares its weakest holding with the strongest instrument it does not own, and explains in its thesis when it keeps the portfolio unchanged. Until now the instructions only said that cash and holding were valid answers and that every trade costs money. Holdings and history carry on, and the universe, limits and evidence packet are unchanged.
- Publication Selected for publication by cli
- Lifecycle Created (forward, signal) by cli
Methodology
- Strategy
- LLM agent (version de4e574c5897)
- What it buys
- A language model chooses from a fixed list of liquid US ETFs and large-cap stocks after each completed session, from an evidence packet (prices, returns, trend and volatility measures, its own holdings) and, where allowed, its own web research. Universe: SPY, QQQ, IWM, DIA, EFA, EEM, VNQ, TLT, IEF, SHY, LQD, HYG, TIP, GLD, SLV, USO, DBC, XLE, XLF, XLK, XLV, XLY, XLP, XLI, XLU, SMH, AAPL, MSFT, NVDA, AMZN, GOOGL, META, TSLA, AVGO, JPM, V, UNH, XOM, JNJ, PG, HD, COST, LLY, WMT, NFLX.
- Sizing
- The model sets absolute target weights; a deterministic controller enforces the book's position count, per-instrument and total exposure limits and turns targets into whole-share orders. Answers that break a limit are rejected, not adjusted.
- Reviews
- After every session's close, until a deadline shortly before the next open. No answer by then is a visible missed review; holdings and exit rules carry on.
- Exits
- The model's new target weights, plus optional exit rules it attaches to new positions (stop, take-profit, maximum holding period, close above an average), which a deterministic supervisor enforces on daily closes even when reviews are missed.
- Execution
- Decisions after each session's completed daily bar; trades at the next eligible session's reference price: Daily bar open: first regular-session IEX trade (not the official opening auction). Modeled execution cost 2 basis points per trade. Valuation: Daily bar close: last regular-session IEX trade (not the official closing auction).
- Fees
- Broker fee profile alpaca-securities-standard (dated schedules only): no commission; SEC fee and FINRA TAF on sales, CAT fee on all trades, aggregated daily and rounded up to the cent.
- Corporate actions
- Dividends accrue on the ex-date for shares held at the prior close and are paid in cash on the payable date; splits adjust share counts. Unadjusted prices.
- Benchmark
- SPY buy and hold (agent cohort), started on the same day with the same capital and cost assumptions.
- Cohort
- Agent cohort, Q4 2026: 1 Oct 2026 to 30 Sep 2027.
- Publication
- Selected for publication 2 Oct 2026, 17:31 UTC, after the book started; its full history is shown.